Hot update bolstered Supernus Pharmaceuticals (SUPN) stock in the After hours
In after-hours trade Tuesday, Supernus Pharmaceuticals (SUPN) shares soared more than 24% percent to $27.99, following the firm revealed promising findings from a trial of its new treatment for attention deficit hyperactivity disorder, or ADHD. Supernus reported Tuesday afternoon that its intended goal was met in a phase 3 trial of the medication, known as […]